Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $6,871 | $4,771 | $4,428 | $1,959 |
| - Cash | $991 | $137 | $193 | $384 |
| + Debt | $481 | $367 | $37 | $33 |
| Enterprise Value | $6,361 | $5,001 | $4,271 | $1,609 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$6 | -$5 | -$3 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$416 | -$337 | -$212 | -$149 |
| % Margin | – | – | – | – |
| Net Income | -$433 | -$352 | -$222 | -$152 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.67 | -2.32 | -1.63 | -1.29 |
| % Growth | -15.1% | -42.3% | -26.4% | – |
| Operating Cash Flow | -$342 | -$293 | -$179 | -$118 |
| Capital Expenditures | -$4 | -$4 | -$11 | -$19 |
| Free Cash Flow | -$346 | -$297 | -$189 | -$137 |